RO4929097
Drug timelines are a Plus or Pro feature.
33 regulatory and trial events tracked for RO4929097, covering 2012-06-11 to 2017-10-18. Get the full timeline:
Most recent: Clinical Trial Update: Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma [Phase 1, Phase 2]